Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine
Journal of Travel Medicine · 2024
DOI: 10.1093/jtm/taae084 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Travel Medicine, 2024. Verfasst von Vera Buerger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Valneva Austria GmbH, Campus Vienna Biocenter, 3103 Vienna, Austria. Hauptthemen laut MEDLINE: Vaccines, Attenuated, Chikungunya Fever, Antibodies, Viral, Viral Vaccines. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Valneva Austria, GmbH, Coalition for Epidemic Preparedness Innovation.
Abstract (Originalsprache)
Background
Chikungunya is a serious and debilitating viral infection with a significant disease burden. VLA1553 (IXCHIQ®) is a live-attenuated vaccine licensed for active immunization for prevention of disease caused by chikungunya virus (CHIKV).
Methods
Immunogenicity following a single dose of VLA1553 was evaluated in healthy adults aged ≥18 years in two Phase 3 trials [N = 656 participants (per protocol analysis set)]. Immunogenicity data to 180 days post-vaccination [geometric mean titres (GMTs), seroresponse rate, seroconversion rate] were pooled for the two trials. A comparison of subgroups based on age, sex, body mass index (BMI), race and baseline seropositivity was included. All analyses were descriptive.
Results
Most participants were aged 18–64 years (N = 569/656 [86.7%]), there were slightly more females (N = 372/656 [56.7%]), most were not Hispanic/Latino (N = 579/656 [88.3%]), and most were White (N = 517/656 [78.8%]). In baseline seronegative participants, GMT peaked at Day 29 post-vaccination, and subsequently declined slightly but remained elevated until Day 180. At Days 29, 85 and 180, seroresponse rate was 98.3, 97.7 and 96.4% and seroconversion rate was 98.5, 98.4 and 98.2%. There were no differences in seroresponse rate in participants aged 18–64 years or ≥65 years at Day 29 (98.1 vs 100%), Day 85 (97.4 vs 100%) and Day 180 (96.3 vs 96.5%) nor based on sex, BMI, ethnicity or race. An immune response was shown in a small heterogenous population of baseline seropositive participants, with GMTs showing the same trend as baseline seronegative participants.
Conclusions
A single dose of VLA1553 elicited a very strong immune response by Day 29 that remained elevated at Day 180 in both baseline seronegative and seropositive participants in a combined evaluation of two Phase 3 trials. The vaccine was similarly immunogenic in participants aged ≥65 years and 18–64 years, and there were no differences based on subgroup analyses for sex, BMI, ethnicity or race.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Valneva Austria GmbH, Campus Vienna Biocenter, 3103 Vienna, Austria.
- Assign Data Management and Statistics GmbH, Stadlweg 23, 6020 Innsbruck, Austria.
Förderung
- Valneva Austria, GmbH
- Coalition for Epidemic Preparedness Innovation
Zitieren
APA
Buerger, V., Maurer, G., Kosulin, K., Hochreiter, R., Larcher-Senn, J., Dubischar, K., & Eder-Lingelbach, S. (2024). Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taae084
Vancouver
Buerger V, Maurer G, Kosulin K, Hochreiter R, Larcher-Senn J, Dubischar K, et al. Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine. Journal of Travel Medicine. 2024. doi:10.1093/jtm/taae084
BibTeX
@article{Buerger2024,
author = {Buerger, Vera and Maurer, Gabriele and Kosulin, Karin and Hochreiter, Romana and Larcher-Senn, Julian and Dubischar, Katrin and Eder-Lingelbach, Susanne},
title = {Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccine},
journal = {Journal of Travel Medicine},
year = {2024},
doi = {10.1093/jtm/taae084}
}
EUVIMED